Background: Green tea is a beverage widely used by lung cancer patients and the public for its purported anticancer properties. The authors conducted a systematic review of green tea for the treatment and prevention of lung cancer. Methodology: Six electronic databases were searched from inception until November 2011 for human interventional and preclinical evidence pertaining to the safety and efficacy of green tea for lung cancer. Results: A total of 84 articles met inclusion criteria: two Phase I trials, three reports of one surrogate study, and 79 preclinical studies. There is a lack of controlled trials investigating green tea for lung cancer. Two Phase I studies showed no objective tumor responses at the maximum tolerated dose, ranging from 3 to 4.2 g/m 2 green tea extract (GTE) per day. Four cups of green tea daily decreased DNA damage (8OH-dG) in smokers. Human studies indicate that 800mg of green tea catechins daily does not alter activity of the CYP2D6, CYP1A2, CYP3A4 and CYP2C9 enzymes, however in vitro evidence suggests that green tea may bind to and reduce the effectiveness of bortezomib. Green tea applied topically may improve the healing time of radiation burns. Conclusions: Although some evidence suggests that chemopreventative benefits can be accrued from green tea, there is currently insufficient evidence to support green tea as a treatment or preventative agent for lung cancer. Green tea should not be used by patients on bortezomib therapy. Further research is warranted to explore this natural agent for lung cancer treatment and prevention.
Introduction
Lung cancer is one of the most prevalent and fatal cancers, accounting for more than 150 000 deaths in 2010 for the United States alone. 1 Median survival for patients presenting with stage IIIB or IV disease is only 6 to 10 months. 2 In search of better outcomes, cancer patients frequently use natural health products. Up to 50% of cancer patients use some form of complementary and alternative medicine (CAM), and among lung cancer patients who do use CAM, up to 11.5% report taking medicinal teas specifically. 3, 4 Green tea is popular among the public at large as a cancer prevention strategy; however, to date there has been no synthesis of current evidence regarding the safety and efficacy of green tea for use in the treatment and prevention of lung cancer.
Green tea is a beverage made from the leaves of Camellia sinensis that have undergone minimal oxidization and fermentation. Green tea has potent antioxidant activity, and green tea polyphenols (GTPs) are thought to be active in protecting against carcinogen-induced DNA damage as well as in promoting apoptosis of tumor cells and inhibiting angiogenesis. [5] [6] [7] [8] Observational evidence has reproducibly documented an association between green tea consumption and reduced risk of cancer. Specifically, a recent meta-analysis of observational studies reported a trend toward reduced risk of lung cancer recurrence associated with higher intake of green tea. 9 No study, however, has comprehensively reviewed data from all levels of evidence, including intervention trials and preclinical evidence to assess the effects of green tea for lung cancer.
GTPs consist of the catechins: epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gallate, and epicatechin; EGCG is the major green tea catechin. 10 By dry weight, one 120-mL cup of green tea (˜250-500 mg of dried green tea leaf 11, 12 ) typically contains 30% to 40% of total catechins and approximately 25 to 35 mg EGCG. [10] [11] [12] [13] Green tea contains a variable amount of caffeine, ranging from 11 to 20 mg/g dry weight or approximately 2.5 to 10 mg per cup, depending on the method of preparation. 14 The relative amounts of green tea constituents also depend on geography, growth conditions, and method of preparation.
For therapeutic purposes, green tea is often administered as an encapsulated extract (green tea extract, GTE) and standardized to EGCG. In the products used for the studies reviewed here, concentrations ranged from 13.9% to 65% EGCG, 15, 16 with composition up to 80% EGCG in other available products. Polyphenon E is a standardized GTP preparation containing 65% EGCG and has been extensively studied in lung cancer models as well as in preliminary human studies that are unrelated to lung cancer. 17 To synthesize the evidence pertaining to the use of green tea/GTE in lung cancer, we conducted a systematic review of the safety and efficacy of green tea for the treatment and prevention of lung cancer, considering potential interactions with conventional chemotherapy and radiation therapy.
Methodology
We searched the following electronic databases for all levels of evidence pertaining to green tea and lung cancer from inception to February 2010: PubMed, EMBASE, CINAHL, Alt HealthWatch, Cochrane, and the National Library of Science and Technology. We used a broad-based MeSH and keyword approach combining clinical (lung cancer) and therapeutic (green tea) search terms, as listed in Table 1 . An initial search was conducted in June 2008 (HF), and this was repeated by an independent researcher in June 2009 (DAK). An updated search was conducted in November 2011. Records from both searches were pooled and screened for inclusion. As the first search identified relatively few studies of interest in the databases CINAHL, Alt HealthWatch, Cochrane, and the National Library of Science and Technology, the updated search was conducted only in PubMed and EMBASE.
Screening of studies was initially conducted based on title review. In the event of uncertainty, abstracts and/or full texts were also reviewed. Only English language publications were included. Human trials had to assess the efficacy of green tea/GTE in people with lung cancer for the purposes of treatment or prevention of lung cancer, reduction of side effects and toxicities associated with chemotherapy or radiation therapy, or assessment of potential interactions with these therapies in patients with lung cancer. Biomarker studies were included if they examined end points directly related to lung cancer risk or pathogenesis. All types of lung cancers (small-cell lung cancer, non-small-cell lung cancer, and mesothelioma) were included.
We did not include observational studies because of the fact that 2 systematic reviews on green tea consumption and risk of lung cancer have recently been published; however, we discuss the findings from these studies in brief here to ensure full comprehensiveness of the evidence as presented by our review.
For inclusion, preclinical studies had to be conducted using lung cancer models and examine either anticancer effects of orally administered green tea and/or GTE or their interaction with conventional chemotherapy or radiation therapy. Studies that examined synthetic catechins or black tea were excluded. Preclinical studies were categorized as positive, negative, neutral, or mixed. The term positive designates studies that found significant anticancer effects from at least 1 of the forms/extracts of green tea tested in models of lung cancer, alone or additively with other agents; negative designates studies that found significant procarcinogenic effects alone or in combination with other agents; and neutral designates studies that found no significant beneficial effect nor any evidence of harm. In the absence of reported levels of significance, the authors' interpretation was used to guide classification.
We piloted data extraction sheets and conducted the extractions in duplicate to assess interresearcher reliability. On completion of data extraction for more than 50% of human-level studies, there were no major inconsistencies, and further duplication of data extraction was deemed unnecessary. Data on quality and efficacy were extracted. Extraction sheets were prepared based on the Consolidated Standards of Reporting Trials (CONSORT) statement for human trials 18, 19 and the Score for Assessment of Physical Experiments on Homeopathy 20 for preclinical studies, respectively. Randomized trials were assessed for quality using the Jadad score. 21
Results
A total of 84 studies were included for full analysis. Of these, 2 were phase I studies conducted in lung cancer patients, 3 reports were of a single clinical surrogate trial in smokers, and 79 were preclinical studies. No randomized controlled trials (RCTs) were identified that assessed green tea for the treatment or prevention of lung cancer. Figure 1 shows the literature flowchart.
Preclinical Evidence
Of the 79 included studies reviewed, 72 showed anticancer effects for green tea ( Table 2) . [6] [7] [8] In vivo, 28 of these studies supported a chemopreventive effect for green tea against lung cancer when given following exposure to environmental tobacco smoke 22, 28 and tobacco-specific carcinogens, 6, 17, 23, 25, 27, 29, 30, 33, 34, 37, 39, 41, [45] [46] [47] 53, 54, [57] [58] [59] [60] or in models testing for spontaneous tumorigenesis (eg, decreased lung tumor incidence, size, or multiplicity). 51 Five studies found green tea to increase animal survival in vivo, 29, 44, 50, 54, 55 and 3 studies showed growth inhibitory effects on in vivo tumors. 30, 40, 41 In vitro, the most supported mechanisms were: growth inhibition and/or antiproliferative activity in tumor cells (n = 24), 23 Includes effects on tumor growth observed in animal models of metastasis to the lungs, such as that induced by intravenous or subcutaneous injection of lung cancer cells as well as results from in vitro studies on markers such as VEGF or invasive capacity. Thus, results from animal models of metastasis are differentiated from effects on primary tumor growth induced by administration of carcinogen and are detailed under this column, whereas measures of (nonmetastatic) primary tumor growth are categorized under "Anticancer Effect."
(n = 3). 30, 71, 79 Two studies in mice and in vitro showed that green tea may induce phase II liver enzymes, possibly contributing to a chemopreventive effect and affecting drug metabolism; however, this has not been shown in human studies. 63, [98] [99] [100] One in vitro study found that green tea reduced reactive oxygen species-induced apoptosis in lung cancer cells treated with photodynamic therapy. 70 Preclinical studies in lung cancer models have indicated an ability of green tea to potentiate the effects of certain drugs used as or with chemotherapy, including cisplatin, 46 dacarbazine, 44 erlotinib, 31 dexamethasone, 47 and sulindac. 77 Human Trials Surrogate trials. One RCT assessed for a shift in a biomarker of DNA damage and repair and found that green tea consumption at a dose of four 8-oz cups per day significantly reduced oxidative DNA damage in heavy smokers by 31% compared with baseline. The surrogate measured was urinary excretion of 8-hydroxydeoxyguanosine (8-OHdG), [101] [102] [103] which is elevated in current smokers compared with never smokers or those who have recently quit and is thought to represent DNA damage caused by smoking and repair. 104 The study found a decrease after 4 months from 8.7 to 6.0 ng/mg creatinine among patients taking green tea, a value similar to that in nonsmokers (7.36 ng/mg) according to Kanaya et al. 105 Phase I trials. Two phase I trials assessed the use of GTE in lung cancer patients 15, 16 (see Tables 3 and 4 ). Both doseranging trials were conducted in patients with late-stage disease; the study by Laurie et al, 15 was limited to lung cancer exclusively (small cell or non-small cell), whereas the study by Pisters et al, 16 was conducted in patients with various cancers, including 21 patients with non-small-cell lung cancer and 3 with mesothelioma. Both studies used a GTE of similar composition, with approximately 13% EGCG and 6.8% caffeine. No objective tumor responses were seen in either study; however, 10 of 17 (58.8%) patients and 10 of 49 (20.4%) patients, respectively, achieved disease stabilization for up to 4 to 6 months. In both these trials, a similar maximum tolerated dose (MTD) for GTE was found: 3.0 g/ m 2 per day in 1 study 15 and either 1.0 g/m 2 3 times a day or 4.2 g/m 2 once daily in the other, 16 with the divided dosing (1.0 g/m 2 ) 3 times daily being better tolerated. 16 This daily dosing of GTE is approximately equivalent to 4.8 to 6.7 g GTE 3 times daily or 7 to 8 cups (120 mL/cup) of tea 3 times daily. 16 In the study by Laurie et al, 15 mild side effects (grade 1 or 2) included fatigue, dyspepsia, diarrhea, headache, anxiety, and insomnia and were attributed in part to the caffeine content. Neurological symptoms (anxiety, insomnia, and headache) and fatigue occurred at the entry-level dose of 0.5 g/m 2 , whereas digestive symptoms occurred at 1.0 to 2.0 g/m 2 . Grade 3 side effects that were dose-limiting toxicities were diarrhea, nausea, and hypertension, which occurred at 4.0 g/m 2 per day; all symptoms improved through dose reduction. 15 In the study by Pisters et al, 16 GTE was well tolerated, with mild side effects, including nausea, restlessness, pain, polyuria, and polydipsia beginning at a dose of 1.0 g/m 2 per day, and this increased dramatically at a dose above 3.0 g/m 2 . Dose-limiting toxicities included gastrointestinal upset and central nervous system stimulation (insomnia and agitation), attributed to the caffeine content. Pharmacokinetic analysis suggested that there was a dosedependent accumulation of caffeine levels but not in levels of EGCG. 16 Investigators concluded that although GTE is unlikely to have a significant direct cytotoxic effect, it should be studied further for potential chemotherapyenhancing and cytostatic properties. 15 
Interactions
Two studies investigating the impact of decaffeinated GTE for 2 to 4 weeks in healthy participants on CYP2D6, CYP1A2, CYP3A4, and CYP2C9 enzymes found no clinically significant impact on enzyme function. 99, 100, 106 Extracts used were (1) 800 mg/d mixed catechins, 99 approximately the amount found in ten 120-mL cups of tea 15, 106 or in crude GTE at half the MTD, and (2) 800 mg EGCG, 100 approximately the amount found in 20 cups of tea, 106 close to the MTD. (Because extracts of differing composition possess differing biological activity, these estimates are given to provide a more concrete sense of volume involved, rather than to suggest substitutions in therapeutic administration.) A 2009 in vitro study found that EGCG may interact with bortezomib, binding with the cancer drug and blocking its therapeutic effect. The authors advised that patients undergoing treatment for multiple myeloma and mantle cell lymphoma or who are otherwise taking this medication avoid consumption of green tea or any products containing GTE. 107 More extensive investigations with green tea and other chemotherapeutic drugs have not been carried out in humans.
Patients undergoing radiation treatments often experience radiation-induced skin toxicity. Pajonk et al 108 studied the effectiveness of green tea applied to skin regions with grade 2+ toxicity. Green tea compresses applied to the affected skin regions 3 times per day for 10 minutes significantly reduced the duration of the skin reaction from 26 days to 16.5 days in participants receiving radiation for head and neck tumors and from 22 days to 16 days for those receiving chemoradiotherapy for cancers in the pelvic region.
Discussion
Dose-ranging trials have demonstrated the safety and tolerability of GTE in advanced lung cancer patients at 
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Integrative Cancer Therapies 12 (1) dosages from to 3.0 to 4.2 g/m 2 /d with improved tolerability using divided doses. 15, 16 There is at present a lack of evidence supporting direct cytotoxic effects for green tea as an anticancer therapy in lung cancer patients; however, existing evidence does suggest that green tea/GTE may be more useful instead as a cytostatic agent in conjunction with standard treatment, where it may prolong the period of disease stabilization. 15, 16 Preclinical evidence suggests that GTE may potentiate the anticancer effects of chemotherapy drugs 44, 46, 84 ; however, further investigation is required before green tea can be recommended for this purpose in humans. 74 Although there is no evidence from phase III or IV studies, green tea/GTE should not be used in conjunction with bortezomib at this time. 107 GTE appears to be better tolerated when given in divided doses, and common side effects include gastrointestinal upset and symptoms of central nervous system stimulations such as insomnia, anxiety, and headache. 15, 16 Observational evidence pertaining to the chemopreventive effects of green tea is conflicting. In a recent systematic review of observational data, Yuan 109 reported that of 12 included studies, 5 found a "statistically significant inverse association between green tea intake or dietary catechins and lung cancer risk," 1 study reported significantly increased risk associated with higher green tea intake, 4 studies showed no significant associations, and 2 studies "reported a relative risk that was close to one" (p. 895). A 2009 meta-analysis of 22 observational studies by Tang et al 9 found a "borderline significant association between highest green tea consumption and reduced risk of lung cancer (relative risk [RR] = 0.78; 95% confidence interval [CI] = 0.61-1.00)." In addition, Tang et al 9 found that intake of 2 cups of green tea per day was associated with an 18% decreased risk of developing lung cancer (RR = 0.82; 95% CI = 0.71-0.96). An observational study examining surrogates of DNA damage found that green tea consumption in smokers reduced the frequency of sister chromatid exchange to that found in nonsmoking individuals, 110 and similar findings were reported from an RCT of current smokers. Although there was no protective effect overall, among those individuals with the GSTM1 and GSTT1 genotypes, consumption of green tea significantly reduced the urinary marker of DNA damage, urinary 8-OHdG. [101] [102] [103] Other observational studies that conducted separate analyses in smoking individuals report mixed findings, with 1 study finding protective effects for higher amounts of green tea consumption in smokers 111 and 2 studies finding no such effects. 112, 113 It should be noted that most of the observational studies were conducted solely in Asian populations. With the potential for differing effects in individuals of different genotypes, generalizing to a more heterogeneous North American population needs to be done with caution. Further investigation of green tea's potential chemoprotective effect is warranted. 
Other Cancers
There is a lack of clinical evidence regarding green tea use in lung cancer. However, although evidence around green tea's effects in other cancer types cannot be directly extrapolated to lung cancer, clinical evidence showing beneficial effects from green tea/GTE administration on premalignant conditions does lend some support to the hypothesis that green tea may also be effective for the prevention of lung cancer. Doses of between 600 to 3000 mg GTE per day has been shown to (1) improve clinical response rates in patients with leukoplakia and oral premalignant lesions, 114, 115 (2) reduce the incidence of metachronous adenomas in patients who underwent polypectomy for prevention of colorectal cancer, 116 (3) benefit cervical dysplasia, 117 and (4) reduce the incidence of prostate cancer by almost 80% in patients with high-grade prostate intraepithelial neoplasia. 118 Green tea has also been shown to reduce absolute lymphocyte count and lymphadenopathy in patients with chronic lymphocytic leukemia. 119 
Dose
At present there is insufficient evidence from clinical trials on which to base dose recommendations for lung cancer treatment or prevention. The MTD appears to range between 3.0 and 4.2 g/m 2 per day, equivalent to approximately 7 to 8 cups (150 mL) of tea 3 times daily. 15, 16 No data are available indicating the therapeutic dose for use in lung cancer, if such is found; however, it is worth noting that this MTD exceeds the range of therapeutic doses used by the trials in other cancer types cited above. Observational evidence supporting the anticancer effects of green tea shows a variable level of therapeutic intake, with up to 10 cups per day or the equivalent of 1500 mL in 1 study 120 and intakes of 3 cups per day in another, 113 both showing benefit. A recent Cochrane review cited the "desirable green tea intake" for cancer prevention as 3 to 5 cups per day (up to 1200 mL/d), providing a minimum of 250 mg of catechins per day, and concluded that green tea appears to be "safe at moderate, regular and habitual use." 121 A recent meta-analysis by Tang et al 9 found a significant chemoprotective effect against lung cancer at an intake of 2 cups per day (300 mL) or more (RR = 0.82; 95% CI = 0.71-0.96).
Green tea's well-established antioxidant effects raise potential points of concern when used alongside chemotherapy. [122] [123] [124] [125] [126] It may be appropriate to schedule administration around chemotherapy as described by Seely et al 127 to minimize risk of interaction between interventions. In brief, antioxidants should be administered after 5 elimination half-lives (t 1/2 ) of the chemo drug have elapsed when given after chemotherapy and no sooner than 5 times the t 1/2 of green tea/catechins before chemotherapy. This minimizes the potential for pharmacodynamic interactions between the 2 agents because 5 × (t 1/2 ) is considered the time required for a substance to be cleared (>90%) from the body. Alternately, if the purpose of therapy is to obtain a positive interaction between the 2 agents, it would be important to administer them within a closer window of time. There is some preclinical evidence showing that green tea may reverse multidrug resistance in models of other cancer types [128] [129] [130] ; however, at this time, there is insufficient clinical evidence to support a purposeful strategy of therapeutic combination with chemotherapy.
Conclusion
There is insufficient clinical evidence that green tea is effective at chemoprevention or treatment of lung cancer. GTE appears to be safe at dosages of up to 3.0 g/m 2 /d in advanced lung cancer patients; however, caution should be applied for patients actively receiving chemotherapies, particularly bortezomib, because of unknown effects on drug metabolism and activity. Regular consumption of green tea as a beverage may exert a modest protective effect against lung cancer, but further clinical studies are needed to confirm this. The level of green tea consumption required to be chemopreventive is estimated by some as equivalent to 1500 mL of tea daily, although based on studies reviewed here, the range of the therapeutic dose varies considerably, starting from 1 cup daily to 10 or more per day.
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